anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a cepharanthine oral disintegrating tablet and a preparing technology thereof. The cepharanthine oral disintegrating tablet has the functions of promoting reticuloendothelial systems, resisting metabolous reaction, etc., and is used for preventing and treating leukopenia caused by radiotherapy and chemotherapy. The cepharanthine oral disintegrating tablet uses cepharanthine as raw materials and filling agent, disintegrating agent, correcting agent, flow assisting agent, lubricating agent, etc. as auxiliary materials. Adhering agent or coating materials can be used according to different situations, proper effervescent agent can be added according to the situations, and the cepharanthine oral disintegrating tablet can be tabletted by a tabletting machine. The cepharanthine oral disintegrating tablet of the present invention has the advantages of good friability, quick disintegration, good mouth feel, no gravel taste, low production cost and convenient carrying, storage, transportation and application.
The I-AVI group were involved in a regular tennis training process, two times a week for one hour. Additionally right after the tennis lessons they played a Virtua Tennis 4 active video game for 20 minutes per participant. They use the playstation kinect console. The intervention lasted 6 months.
Water-swellable crosslinked polyacrylate elastomers comprising at least one phosphate or phosphonate moiety and methods of making are provided. The elastomer may advantageously be included in a skin treatment composition. The swelling elastomers according to the invention are particularly well suited for inclusion in skin-tightening cosmetics. The elastomer may be formulated to form a film. The elastomer according to a preferred embodiment of the present invention may adhere to the skin when applied to the skin and shrink as it dries. This may provide skin tightening, lifting and wrinkle smoothing effects when dry. This effect may temporarily mask the appearance of wrinkles. The elastomer may be the reaction product of reaction components comprising: a component having from 3 to 60 carbon atoms containing acrylate or methacrylate moieties and a component having from 3 to 60 carbon atoms containing phosphate or phosphonate moieties. The reactive component may further comprise a siloxane component.
Liver sinusoidal endothelial cells (LSECs) are liver-specific endothelial cells with the highest permeability than other mammalian endothelial cells, characterized by the presence of fenestrae on their surface, the absence of diaphragms and the lack of basement membrane. Located at the interface between blood and other liver cell types, LSECs mediate the exchange of substances between the blood and the Disse space, playing a crucial role in maintaining substance circulation and homeostasis of multicellular communication. As the initial responders to chronic liver injury, the abnormal LSEC activation not only changes their own physicochemical properties but also interrupts their communication with hepatic stellate cells and hepatocytes, which collectively aggravates the process of liver fibrosis. In this review, we have comprehensively updated the various pathways by which LSECs were involved in the initiation and aggravation of liver fibrosis, including but not limited to cellular phenotypic change, the induction of capillarization, decreased permeability and regulation of intercellular communications. Additionally, the intervention effects and latest regulatory mechanisms of anti-fibrotic drugs involved in each aspect have been summarized and discussed systematically. As we studied deeper into unraveling the intricate role of LSECs in the pathophysiology of liver fibrosis, we unveil a promising horizon that pave the way for enhanced patient outcomes.
The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
Acceptance and Commitment Therapy for Moral Injury (ACT-MI) is a novel treatment protocol detailing the application of ACT for recovery from moral injury. ACT-MI is designed to help Veterans learn to interact differently with moral emotions and engage meaningfully in their lives. The intervention is group-based and spans twelve, 90-minute sessions. The current ACT-MI protocol was developed through an iterative process in which authors generated and refined the intervention based on clinical interactions with Veterans currently reporting moral injury.
The invention discloses a preparation method and application of total flavonoids in stem leaves of chrysanthemum. The total flavonoids in the stem leaves of chrysanthemum are prepared by extracting the stem leaves of chrysanthemum through use of aquiferous ethanol and enriching through macroporous resins. The weight percentage content of the total flavonoids in the stem leaves of chrysanthemum, provided by the invention, is not less than 50 %, wherein the weight percentage content of buddleoside is not less than 1.0 % and the weight percentage content of luteolin is not less than 1.0 %. The total flavonoids in the stem leaves of chrysanthemum, provided by the invention, can be prepared into solid preparations and liquid preparations with different officinal excipients. The total flavonoids in the stem leaves of chrysanthemum, provided by the invention, are functioned in resisting oxidation, increasing coronary artery flow, resisting thrombus and the like; the total flavonoids in the stem leaves of chrysanthemum are used as crude materials and can be used as medicaments for treating coronary heart disease with the addition of preparations prepared from different officinal excipients. The total flavonoids in the stem leaves of chrysanthemum, provided by the invention, are prepared by performing nonhazardous treatment and refining on the raw material of stem leaves of chrysanthemum, which are medicinal materials in medicine food homology, and have the advantages of definite therapeutic effect, clear officinal material base, low toxic or side effects and the like.
The invention comprises tetradehydro-reserpic acid of the formula <FORM:0822723/IV (a)/1> and its salts, esters and O-acylated esters. These are made from reserpic acid, reserpic acid esters, O-acylated reserpic acid esters and the corresponding 3-iso-compounds (or salts thereof) by treatment with an oxidising agent having a potential of - 1.7 volts or higher, e.g. lead tetraacetate, lead dioxide in acetic acid, maleic acid and palladium black, or oxygen in acetic acid with a platinum catalyst.  The catalytic methods are preferred for dehydrogenating the free acid.  The products may be modified as follows: free acids converted into salts with bases; esters converted by alkaline hydrolysis or by alcoholysis to the free hydroxy-esters or to the hydroxy-acids; free carboxylic groups esterified with a diazoalkane or with an alkanol and acid catalyst; free hydroxyl groups esterified with an acid halide or anhydride; any of the above converted into salts with acids. Examples show the dehydrogenation of (1) reserpine with lead tetra-acetate in acetic acid; product is obtained as hydrochloride and can be hydrolysed to methyl tetradehydro-reserpate and tetradehydro-reserpic acid (hydrochloride); (2) methyl reserpate with lead tetra-acetate in acetic acid; product is obtained as hydrochloride and may be esterified to give tetradehydro-reserpine; (3) reserpic acid hydrochloride with maleic acid and palladium black; product (hydrochloride) can be esterified with diazomethane; (4) 3-iso-reserpine with lead tetraacetate in acetic acid; product is obtained as hydrochloride.  3-Iso-reserpic acid and methyl 3-iso-reserpate can be dehydrogenated similarly.  The iso-compounds used as starting materials are prepared as follows: iso-reserpine from reserpine and acetic anhydride, methyl iso-reserpate from methyl reserpate and toluene-p-sulphonic acid, and iso-reserpic acid by hydrolysis of the latter.  Reserpic acid itself and its esters are described in Specification 744,290.  The tetradehydro compounds can be reduced with sodium borohydride to the corresponding 3-isoreserpic acid derivatives.ALSO:Sunscreen compositions contain tetradehydroreserpic acid of the formula <FORM:0822723/VI/1> or its salts, esters and O-acylated esters, particularly tetradehydro-reserpine hydrochloride.  They may be incorporated in hydrophilic ointments containing, e.g., propylene glycol, stearyl alcohol and petroleum jelly, or they may be used as solutions in 70% alcohol.
Methods for performing inference on a generative model are provided. In one aspect, a method includes receiving a generative model in a probabilistic program form defining variables and probabilistic relationships between variables, and producing a neural network to model the behaviour of the generative model. The input layer includes nodes corresponding to the variables of the generative model, and the output layer includes nodes corresponding to a parameter of the conditional marginal of the variables of the input layer. The method also includes training the neural network using samples from the probabilistic program. A loss function is provided for each node of the output layer. The loss function for each output node is independent of the loss functions for the other nodes of the output layer. The method also includes performing amortised inference on the generative model. Systems and machine-readable media are also provided.
Doxorubicin (DOX), a widely used chemotherapy agent in cancer treatment, encounters limitations in clinical efficacy due to associated cardiotoxicity. This study aims to explore the role of AKT serine/threonine kinase 2 (AKT2) in mitigating DOX-induced oxidative stress within the heart through both intracellular and extracellular signaling pathways. Utilizing Akt2 knockout (KO) and Nrf2 KO murine models, alongside neonatal rat cardiomyocytes (NRCMs), we systematically investigate the impact of AKT2 deficiency on DOX-induced cardiac injury. Our findings reveal that DOX administration induces significant oxidative stress, a primary contributor to cardiac injury. Importantly, Akt2 deficiency exhibits a protective effect by alleviating DOX-induced oxidative stress. Mechanistically, Akt2 deficiency facilitates nuclear translocation of NRF2, thereby suppressing intracellular oxidative stress by promoting the expression of antioxidant genes. Furthermore, We also observed that AKT2 inhibition facilitates superoxide dismutase 2 (SOD2) expression both inside macrophages and SOD2 secretion to the extracellular matrix, which is involved in lowering oxidative stress in cardiomyocytes upon DOX stimulation. The present study underscores the important role of AKT2 in mitigating DOX-induced oxidative stress through both intracellular and extracellular signaling pathways. Additionally, our findings propose promising therapeutic strategies for addressing DOX-induced cardiomyopathy in clinic.
PURPOSE:To obtain the subject pigment suitable for a colorant by adding an aqueous solution containing iron ions to an aqueous suspension of lamellar mica particles, further adding an aqueous solution of an alkali metal hydroxide or carbonate and coating the mica particles with black iron oxide. CONSTITUTION:An aqueous suspension of lamellar mica particles is stirred with heating in advance. On the other hand, urea and an oxidizing agent capable of oxidizing a ferrous salt are dissolved in an iron ion-containing aqueous solution having the (Fe<3+>/Fe<2+>) ratio adjusted to (0.01-0.4) and the resultant solution is then added to the above-mentioned suspension. An aqueous solution of an alkali metal hydroxide or a alkali metal carbonate, e.g. sodium hydroxide is further added thereto to coat the surface of the lamellar mica particles with black iron oxide. The resultant coated lamellar mica particles are then filtrated, water washed and subsequently heat treated at room temperature or <=200 deg.C in an atmosphere of oxygen or air, thus obtaining the objective pigment.
PROBLEM TO BE SOLVED: To screen the subject substance by culturing a target cell together with a HIV, a carcinogenetic promoter and a candidate substance of anticarcinogenic promoter and discriminating the anticarcinogenic characteristics of the candidate substance using the death rate of the target cell as an index. SOLUTION: A cultured cell of human lymphocyte (e.g. CEMX 174 cell, etc.), is cultured in the presence of an AIDS virus such as human AIDS virus (HIV)-1IIIB strain, a carcinogenetic promoter such as phorbol myristate acetate, etc., and a candidate substance of an anticarcinogenic promoter. Then the target cell is brought into contact with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H- tetrazolium bromide, etc., as a coloring matter and cultured. The death rate of the target cell is obtained by using the amount of the coloring matter derived from the coloring matter taken in the target cell. The anticarcinogenic characteristics of the candidate substance of the anticarcinogenic promoter are discriminated by using the death rate of the target cell as an index to screen an anticarcinogenic promoter substance.
Patients receive abiraterone acetate (1,000 mg daily) plus prednisone (5mg once daily) in combination with enzalutamide (160 mg daily) and LHRHa. Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
Treatment is sequential, Ramucirumab (IMC-1121B) will be administered before FOLFIRI ((Irinotecan + Folinic acid + 5-Fluorouracil). FOLFIRI will be administered each cycle and Ramucirumab (IMC-1121B) will be administered beginning from Cycle 2 (2-week cycle).
The technique applied to the Instrumental Group was performed with the patient supine in the same position as the Manual Group . It was previously instructed the subject how to proceed with the cushion Occipivot® , indicating the installation location and method of affixing , correcting him if the application was inadequate. The subject placed the cushion Occipivot® under the suboccipital region and told him he had to stay in that position for 5 minutes. A physiotherapist warned the patient at the end of the application time so that the subject had to be aware not to control it.
Subjects previously vaccinated with Pandemrix vaccine received 1 first dose of Havrix vaccine (subjects aged above 15 years) or Havrix-Junior vaccine (subjects aged 15 years and below). A second dose was given outside the study setting, at Month 6. All vaccines were administered in the deltoid region of the non-dominant arm on Day 0.
There are over 1.2 million new cases of colorectal cancer and 600,000 deaths worldwide. The liver is the dominant site of metastases. Approximately 20-25% of patients with advanced colorectal cancer will be candidates for resection/ablation of all sites of metastatic disease.1 Unfortunately, despite resection/ablation of all metastatic sites only about 20% of these patients are ultimately cured.1 An effective adjuvant agent would prevent tumor recurrence.

Aflibercept and bevacizumab are effective when combined with FOLFIRI for metastatic colon cancer. Neither has been tested in a randomized study in the adjuvant setting for patients with resected metastatic disease. Since aflibercept more effectively inhibits all forms of VEGF including VEGF-A, VEGF-B and PIGF, in striking contrast to bevacizumab which inhibits only VEGF-A, aflibercept likely will be more effective than bevacizumab as a single agent in the adjuvant metastatic setting. Therefore, we propose a randomized study of adjuvant aflibercept for patients metastatic colorectal cancer who have received 10-12 cycles of perioperative FOLFOX and have had had a complete response to all sites of metastases after chemotherapy and local modalities such as surgical resection or ablation. SBRT may also be used to produce a complete response in a metastatic site not easily amenable to surgery or ablation. Only patients with very high risk of recurrence, defined as 3 or more metastatic sites, will be included in this study.
The invention mainly discloses a method and a device for generating a prediction model for predicting the severity of pneumonia. The method comprises the following steps: clinical information of a subject is acquired. Image information of a subject is acquired. And screening N characteristics from the clinical information and the image information, wherein N is a natural number. And constructing a corresponding classification model by taking at least one of the N characteristics as an input and the pneumonia severity as an output. And training corresponding classification models by taking N characteristics of a plurality of examinees as training samples, and determining the classification model with the optimal fitting precision and parameter number as the prediction model in the plurality of classification models based on a preset criterion. By adopting the scheme provided by the invention, the prediction model with low model complexity and high prediction accuracy is generated.
BACKGROUND: Functional assessment using fractional flow reserve (FFR) and anatomical assessment using optical coherence tomography (OCT) are used in clinical practice for patients with intermediate coronary stenosis. Moreover, coronary computed tomography angiography (CTA) is a common noninvasive imaging technique for evaluating suspected coronary artery disease before being referred for angiography. This study aimed to investigate the association between FFR and plaque characteristics assessed using coronary CTA and OCT for intermediate coronary stenosis.
METHODS: Based on a prospective multicenter registry, 159 patients having 339 coronary lesions with intermediate stenosis were included. All patients underwent coronary CTA before being referred for coronary angiography, and both FFR measurements and OCT examinations were performed during angiography. A stenotic lesion identified with FFR ≤0.80 was deemed diagnostic of an ischemia-causing lesion. The predictive value of plaque characteristics assessed using coronary CTA and OCT for identifying lesions causing ischemia was analyzed.
RESULTS: Stenosis severity and plaque characteristics on coronary CTA and OCT differed between lesions that caused ischemia and those that did not. In multivariate analysis, low attenuation plaque on coronary CTA (odds ratio [OR]=2.78; P=0.038), thrombus (OR=5.13; P=0.042), plaque rupture (OR=3.25; P=0.017), and intimal vasculature on OCT (OR=2.57; P=0.012) were independent predictors of ischemic lesions. Increasing the number of these plaque characteristics offered incremental improvement in predicting the lesions causing ischemia.
CONCLUSIONS: Comprehensive anatomical evaluation of coronary stenosis may provide additional supportive information for predicting the lesions causing ischemia.
Pragmatic, randomised, controlled, parallel-group, pilot trial. Trial participants will be patients admitted to St Patrick's University Hospital for treatment of a depressive episode. The investigators aim to recruit up to 20 participants who will be eligible for this study and randomly allocate 10 patients to each group. The participants will undergo usual inpatient care as prescribed by their treating team for the index acute depressive episode. Both participants and assessors will be blind to treatment allocation. Consented participants will be randomly allocated in a 1:1 ratio to a four week course of either once-weekly ketamine or midazolam infusions. Block randomisation will be independently performed. Physical, psychotomimetic and cognitive outcomes will be monitored before, during and after infusions. Blood samples will be taken at four time-points in the first infusion session and before the final infusion for neuroplasticity biomarker studies. Both groups will continue treatment as usual. Participates will also be followed up over a three month period.
Subjects will recieve one 18 mg dose of deflazacort on Day 1, Period 1 and Day 10, Period 2; cohort A. Subjects will receive once daily dosing of rifampin on Day 1, Period 2 through Day 10, Period 2.
INTRODUCTION: Pseudarthrosis after cervical spine surgery represents an underreported and challenging complication. Using a large multi-center surgical database, we sought to: (1) report the incidence of cervical pseudarthrosis, (2) evaluate changes in rates of cervical pseudarthrosis, and (3) describe risk factors for suboptimal outcomes after cervical pseudarthrosis surgery.
METHODS: The American College of Surgeons National Surgical Quality Improvement Program database from 2012 to 2019 was used. The primary outcome was occurrence of a cervical fusion procedure with a prior diagnosis of pseudarthrosis. Fusion for pseudarthrosis was divided into anterior and posterior approaches. Post-operative complications were classified as major or minor. Prolonged LOS was defined as exceeding the 75th percentile for total hospital stay.
RESULTS: A total of 780 patients underwent cervical fusion for pseudarthrosis, and a significant increase in rates of surgery for pseudarthrosis was seen (0.25-1.2%, p < 0.001). The majority of cervical pseudarthrosis was treated with a posterior approach (66.5%). Postoperatively, 38 (4.9%) patients suffered a complication and 247 (31.7%) had a prolonged LOS. The three strongest risk factors for complications and extended LOS were > 10% weight loss preoperatively, congestive heart failure, and pre-operative bleeding disorder.
CONCLUSION: Results from a large multi-center national database revealed that surgery to treat cervical pseudarthrosis has increased from 2012 to 2019. Most pseudarthrosis was treated with a posterior approach. Reoperation to treat cervical pseudarthrosis carried risk, with 5% having complications and 32% having an extended LOS. These results lay the groundwork for a future prospective study to discern the true incidence of cervical pseudarthrosis and how to best avoid its occurrence.
Pulmonary hypertension (PH) is characterized by vascular remodeling predominantly driven by a phenotypic switching in pulmonary artery smooth muscle cells (PASMCs). However, the underlying mechanisms for this phenotypic alteration remain incompletely understood. Here, we identified that RNA methyltransferase METTL3 is significantly elevated in the lungs of hypoxic PH (HPH) mice and rats, as well as in the pulmonary arteries (PAs) of HPH rats. Targeted deletion of Mettl3 in smooth muscle cells exacerbated hemodynamic consequences of hypoxia-induced PH and accelerated pulmonary vascular remodeling in vivo. Additionally, the absence of METTL3 markedly induced phenotypic switching in PASMCs in vitro. Mechanistically, METTL3 depletion attenuated m6A modification and hindered the processing of pri-miR-143/145, leading to a downregulation of miR-143-3p and miR-145-5p. Inhibition of hnRNPA2B1, an m6A mediator involved in miRNA maturation, similarly resulted in a significant reduction of miR-143-3p and miR-145-5p. We demonstrated that miR-145-5p targets Krüppel-like factor 4 (KLF4) and miR-143-3p targets fascin actin-bundling protein 1 (FSCN1) in PASMCs. The decrease of miR-145-5p subsequently induced an upregulation of KLF4, which in turn suppressed miR-143/145 transcription, establishing a positive feedback circuit between KLF4 and miR-143/145. This regulatory circuit facilitates the persistent suppression of contractile marker genes, thereby sustaining PASMC phenotypic switch. Collectively, hypoxia-induced upregulation of METTL3, along with m6A mediated regulation of miR-143/145, might serve as a protective mechanism against phenotypic switch of PASMCs. Our results highlight a potential therapeutic strategy targeting m6A modified miR-143/145-KLF4 loop in the treatment of PH.